Merck's Pipeline Potential Unlocks Undervalued Mega-Cap Status
Merck's recent surge in stock price may be attributed to the success of its experimental mRNA cancer vaccine in collaboration with Moderna. The achievement, which exhibited significant effectiveness, led to a notable increase in buying activity due to immediate revenue potential in oncology. However, this was not the primary factor driving Merck's annual gain.
The true driver behind the company's performance is its systematic approach to addressing the concern of KEYTRUDA patent expiration. For years, shareholders have been anxious about what would happen after the blockbuster drug loses exclusivity. Merck's leadership has responded with a consistent stream of clinical and regulatory successes, transforming the company from one on the brink of a patent expiration to one that is building a reliable pathway for steady earnings growth.
The pivotal event was the FDA's approval of LIPFENDRA, an oral PCSK9 inhibitor for individuals with high cholesterol. This daily pill can reduce LDL cholesterol by as much as 60% when used in conjunction with a statin, disrupting a market that has been primarily reliant on injectables. Merck also reported favorable Phase III results for sac-TMT in endometrial cancer and tulisokibart for ulcerative colitis.
With clinical data solidifying, management has outlined future expectations, estimating a pipeline with over $70 billion in commercial potential spread across more than 20 new products. This figure serves as a compelling counter-narrative to the market's fixation on KEYTRUDA revenue gap. The significant stock revaluation indicates that Wall Street now confidently endorses this projection.
Merck is trading at a mere 16x forward earnings, which underlines its undervalued status relative to top-tier competitors. Johnson & Johnson trades at 21.5x forward earnings, while Eli Lilly commands 27x. Even with an over 73% rise in the past twelve months, Merck's valuation suggests more upside potential if they maintain performance.